検索結果

ドライン作成委員会（2019 年） 2)：Z. Pan et al. Invest Ophthalmol Vis Sci. 2011; 52(1): 485-93., P. Rozas et al. Pain 2016; 157(6):1346-62. 等 3)：Y. Sakane et al. JAMA Ophthalmol. 2013;131(10):1331-1338. 「アバレプト®懸濁性...

NewMytear A | OTC Products, etc. | Products | SENJU Pharmaceutical

llergies to medicines or something Persons who have suffered from the following symptom: Severe eye pain Persons diagnosed with the following condition: Glaucoma 2. Stop using this medicine immediatel...

アバレプト懸濁性点眼液0.3％に関するよくあるご質問 | 医療関係者向製品情報（医療用医薬品） | 医療関係者のみなさま | 千寿製薬株式会社

(12th Ed); 2024  7）Pan Z, et al.: Invest Ophthalmol Vis Sci. 2011; 52: 485-493  8）Rozas P, et al.: Pain. 2016; 157: 1346-1362  9）Schnizler K, et al.: J Neurosci. 2008; 28: 4904-4917 10）Andratsch M, e...

NewMytear A | OTC Products, etc. | Products | SENJU Pharmaceutical

llergies to medicines or something Persons who have suffered from the following symptom: Severe eye pain Persons diagnosed with the following condition: Glaucoma 2. Stop using this medicine immediatel...

ye Society (2019) 2)：Z. Pan et al. Invest Ophthalmol Vis Sci. 2011; 52(1): 485-93., P. Rozas et al. Pain 2016; 157(6):1346-62. 3)：Y. Sakane et al. JAMA Ophthalmol. 2013;131(10):1331‐1338. Product Over...